
Anneke C Hesseling

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2107482/publications.pdf Version: 2024-02-01



#	Article	IF	CITATION
1	Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children. Clinical Infectious Diseases, 2022, 74, 1372-1381.	2.9	13
2	Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study. Clinical Infectious Diseases, 2022, 75, 141-151.	2.9	16
3	The Diagnostic Accuracy of Chest Radiographic Features for Pediatric Intrathoracic Tuberculosis. Clinical Infectious Diseases, 2022, 75, 1014-1021.	2.9	6
4	Drug concentration at the site of disease in children with pulmonary tuberculosis. Journal of Antimicrobial Chemotherapy, 2022, 77, 1710-1719.	1.3	3
5	Tuberculous Meningitis in Children: A Forgotten Public Health Emergency. Frontiers in Neurology, 2022, 13, 751133.	1.1	3
6	Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant Tuberculosis. Clinical Infectious Diseases, 2022, 75, 1772-1780.	2.9	8
7	Population pharmacokinetics of ethambutol in African children: a pooled analysis. Journal of Antimicrobial Chemotherapy, 2022, 77, 1949-1959.	1.3	3
8	Coronavirus Disease 2019 (COVID-19) Pharmacologic Treatments for Children: Research Priorities and Approach to Pediatric Studies. Clinical Infectious Diseases, 2021, 72, 1067-1073.	2.9	4
9	Positive <i>Mycobacterium tuberculosis</i> Gastric Lavage Cultures from Asymptomatic Children With Normal Chest Radiography. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 502-508.	0.6	2
10	Tuberculosis prevention in children: a prospective community-based study in South Africa. European Respiratory Journal, 2021, 57, 2003028.	3.1	13
11	Development of a Treatment-decision Algorithm for Human Immunodeficiency Virus–uninfected Children Evaluated for Pulmonary Tuberculosis. Clinical Infectious Diseases, 2021, 73, e904-e912.	2.9	19
12	Carriage of colistin-resistant Gram-negative bacteria in children from communities in Cape Town (Tuberculosis child multidrug-resistant preventive therapy trial sub-study). Southern African Journal of Infectious Diseases, 2021, 36, 241.	0.3	1
13	The Impact of the Evolving Human Immunodeficiency Virus Response on the Epidemiology of Tuberculosis in South African Children and Adolescents. Clinical Infectious Diseases, 2021, 73, e967-e975.	2.9	5
14	Drug susceptibility patterns of Mycobacterium tuberculosis from adults with multidrug-resistant tuberculosis and implications for a household contact preventive therapy trial. BMC Infectious Diseases, 2021, 21, 205.	1.3	6
15	Tuberculosis in persons with sudden unexpected death, in Cape Town, South Africa. International Journal of Infectious Diseases, 2021, 105, 75-82.	1.5	3
16	Health system determinants of tuberculosis mortality in South Africa: a causal loop model. BMC Health Services Research, 2021, 21, 388.	0.9	9
17	Diagnostic utility of bronchoalveolar lavage in children with complicated intrathoracic tuberculosis. Pediatric Pulmonology, 2021, 56, 2186-2194.	1.0	6
18	Improving child tuberculosis contact identification and screening in Lesotho: Results from a mixed-methods cluster-randomized implementation science study. PLoS ONE, 2021, 16, e0248516	1.1	7

#	Article	IF	CITATIONS
19	Early mortality in tuberculosis patients initially lost to follow up following diagnosis in provincial hospitals and primary health care facilities in Western Cape, South Africa. PLoS ONE, 2021, 16, e0252084.	1.1	14
20	Mortality during tuberculosis treatment in South Africa using an 8-year analysis of the national tuberculosis treatment register. Scientific Reports, 2021, 11, 15894.	1.6	5
21	Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial. Journal of Antimicrobial Chemotherapy, 2021, 76, 3237-3246.	1.3	26
22	Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis. Frontiers in Pharmacology, 2021, 12, 722204.	1.6	3
23	Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children. European Respiratory Journal, 2021, 57, 2001756.	3.1	4
24	Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	7
25	Protecting children in low-income and middle-income countries from COVID-19. BMJ Global Health, 2020, 5, e002844.	2.0	26
26	Provider attitudes about childhood tuberculosis prevention in Lesotho: a qualitative study. BMC Health Services Research, 2020, 20, 461.	0.9	10
27	Trends in Drug Resistance in Childhood Tuberculosis in Cape Town, South Africa. Pediatric Infectious Disease Journal, 2020, 39, 604-608.	1.1	6
28	Opportunities for Mobile App–Based Adherence Support for Children With Tuberculosis in South Africa. JMIR MHealth and UHealth, 2020, 8, e19154.	1.8	8
29	Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons. PLoS Medicine, 2019, 16, e1002882.	3.9	27
30	Alternative dosing guidelines to improve outcomes in childhood tuberculosis: a mathematical modelling study. The Lancet Child and Adolescent Health, 2019, 3, 636-645.	2.7	18
31	Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	14
32	The evolving research agenda for paediatric tuberculosis infection. Lancet Infectious Diseases, The, 2019, 19, e322-e329.	4.6	19
33	Morbidity and mortality up to 5 years post tuberculosis treatment in South Africa: A pilot study. International Journal of Infectious Diseases, 2019, 85, 57-63.	1.5	19
34	Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies. PLoS Medicine, 2019, 16, e1002789.	3.9	41
35	Acceptability of a Novel Levofloxacin Dispersible Tablet Formulation in Young Children Exposed to Multidrug-resistant Tuberculosis. Pediatric Infectious Disease Journal, 2019, 38, 608-610.	1.1	8
36	Specimen Pooling as a Diagnostic Strategy for Microbiologic Confirmation in Children with Intrathoracic Tuberculosis. Pediatric Infectious Disease Journal, 2019, 38, e128-e131.	1.1	16

#	Article	IF	CITATIONS
37	Transmission of drug-resistant tuberculosis in HIV-endemic settings. Lancet Infectious Diseases, The, 2019, 19, e77-e88.	4.6	47
38	High Incidence of Tuberculosis Infection in HIV-exposed Children Exiting an Isoniazid Preventive Therapy Trial. Pediatric Infectious Disease Journal, 2018, 37, e254-e256.	1.1	13
39	Clinical Evaluation of a Blood Assay to Diagnose Paucibacillary Tuberculosis via Bacterial Antigens. Clinical Chemistry, 2018, 64, 791-800.	1.5	28
40	The determination of capreomycin in human plasma by LC–MS/MS using ionâ€pairing chromatography and solidâ€phase extraction. Biomedical Chromatography, 2018, 32, e4269.	0.8	1
41	Reply to Drancourt, "Culturing Stools To Detect Mycobacterium tuberculosis― Journal of Clinical Microbiology, 2018, 56, .	1.8	0
42	Effect of Coadministration of Lidocaine on the Pain and Pharmacokinetics of Intramuscular Amikacin in Children With Multidrug-Resistant Tuberculosis: A Randomized Crossover Trial. Pediatric Infectious Disease Journal, 2018, 37, 1199-1203.	1.1	7
43	Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	37
44	Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	16
45	Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP). Trials, 2018, 19, 693.	0.7	36
46	Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis. Lancet Respiratory Medicine,the, 2018, 6, 662-664.	5.2	19
47	Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children. British Journal of Clinical Pharmacology, 2018, 84, 2384-2392.	1.1	23
48	Molecular Detection of Mycobacterium tuberculosis from Stools in Young Children by Use of a Novel Centrifugation-Free Processing Method. Journal of Clinical Microbiology, 2018, 56, .	1.8	23
49	Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. PLoS Medicine, 2018, 15, e1002591.	3.9	96
50	Complementary surveillance strategies are needed to better characterise the epidemiology, care pathways and treatment outcomes of tuberculosis in children. BMC Public Health, 2018, 18, 397.	1.2	14
51	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respiratory Medicine,the, 2017, 5, 291-360.	5.2	459
52	The time has come: sparing injectables in paediatric MDR-TB. Lancet Respiratory Medicine,the, 2017, 5, 245-246.	5.2	2
53	Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis. Expert Opinion on Pharmacotherapy, 2017, 18, 589-598.	0.9	12
54	Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa. Vaccine Journal, 2017, 24, .	3.2	112

#	Article	IF	CITATIONS
55	Stool Culture for Diagnosis of Pulmonary Tuberculosis in Children. Journal of Clinical Microbiology, 2017, 55, 3355-3365.	1.8	38
56	Excellent Treatment Outcomes in Children Treated for Tuberculosis Under Routine Operational Conditions in Cape Town, South Africa. Clinical Infectious Diseases, 2017, 65, 1444-1452.	2.9	29
57	New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1300-1310.	2.5	61
58	Phenotypically resembling myeloid derived suppressor cells are increased in children with HIV and exposed/infected with <i>Mycobacterium tuberculosis</i> . European Journal of Immunology, 2017, 47, 107-118.	1.6	27
59	The impact of drug resistance on the risk of tuberculosis infection and disease in child household contacts: a cross sectional study. BMC Infectious Diseases, 2017, 17, 593.	1.3	13
60	The PREVENT study to evaluate the effectiveness and acceptability of a community-based intervention to prevent childhood tuberculosis in Lesotho: study protocol for a cluster randomized controlled trial. Trials, 2017, 18, 552.	0.7	7
61	BCG vaccination induces HIV target cell activation in HIV-exposed infants in a randomized trial. JCI Insight, 2017, 2, e91963.	2.3	11
62	Tuberculosis Disease during Pregnancy and Treatment Outcomes in HIV-Infected and Uninfected Women at a Referral Hospital in Cape Town. PLoS ONE, 2016, 11, e0164249.	1.1	25
63	Delayed BCG immunization does not alter antibody responses to EPI vaccines in HIV-exposed and -unexposed South African infants. Vaccine, 2016, 34, 3702-3709.	1.7	9
64	Adverse effects of oral second-line antituberculosis drugs in children. Expert Opinion on Drug Safety, 2016, 15, 1369-1381.	1.0	29
65	The safety and tolerability of the second-line injectable antituberculosis drugs in children. Expert Opinion on Drug Safety, 2016, 15, 1491-1500.	1.0	13
66	Reply to Thysen et al. Journal of Infectious Diseases, 2015, 212, 1342-1343.	1.9	1
67	Tuberculosis: opportunities and challenges for the 90–90–90 targets in HIVâ€infected children. Journal of the International AIDS Society, 2015, 18, 20236.	1.2	17
68	Pharmacokinetics and Safety of Moxifloxacin in Children With Multidrug-Resistant Tuberculosis. Clinical Infectious Diseases, 2015, 60, 549-556.	2.9	62
69	Delaying BCG Vaccination Until 8 Weeks of Age Results in Robust BCG-Specific T-Cell Responses in HIV-Exposed Infants. Journal of Infectious Diseases, 2015, 211, 338-346.	1.9	28
70	Successful Treatment of a Child With Extensively Drug-Resistant Tuberculous Meningitis: Figure 1 Journal of the Pediatric Infectious Diseases Society, 2015, 4, e41-e44.	0.6	6
71	Clinical Case Definitions for Classification of Intrathoracic Tuberculosis in Children: An Update. Clinical Infectious Diseases, 2015, 61, S179-S187.	2.9	231
72	Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2015, 59, 6073-6079.	1.4	17

#	Article	IF	CITATIONS
73	Delayed BCG vaccination results in minimal alterations in T cell immunogenicity of acellular pertussis and tetanus immunizations in HIV-exposed infants. Vaccine, 2015, 33, 4782-4789.	1.7	10
74	Linezolid for the treatment of drug-resistant tuberculosis in children: A review and recommendations. Tuberculosis, 2014, 94, 93-104.	0.8	51
75	Consensus Statement on Research Definitions for Drug-Resistant Tuberculosis in Children. Journal of the Pediatric Infectious Diseases Society, 2013, 2, 100-109.	0.6	40
76	The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine, 2007, 25, 14-18.	1.7	220